Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 32.18% is 102% above its 5-year average of -1611.96%, near the high end of its 5-year range (-4622.57%–175.18%).
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): 85.54%.
EBITDA MARGIN
32.18%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
-137.83%
EBITDA MARGIN AVG 5Y
-1611.96%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+123.35%
CURRENT VS 5Y AVG
+102.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$242.50M
EBITDA Margin
6.37%
TTM Avg
-0.39%
3Y Avg
-2.45%
5Y Avg
1.13%
Market Cap
$245.79M
EBITDA Margin
-1.78%
TTM Avg
-948.17%
3Y Avg
-2570.36%
5Y Avg
-2570.36%
Market Cap
$239.25M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$246.29M
EBITDA Margin
-3813.88%
TTM Avg
-3607.01%
3Y Avg
-5701.50%
5Y Avg
-5701.50%
Market Cap
$246.48M
EBITDA Margin
-38.32%
TTM Avg
-70.22%
3Y Avg
-602.02%
5Y Avg
-454.95%
Market Cap
$236.58M
EBITDA Margin
-1441.45%
TTM Avg
-4661.83%
3Y Avg
-5918.79%
5Y Avg
-3944.51%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Q32 Bio Inc. (QTTB) | $242.58M | 32.18% | N/A | -137.83% | -1611.96% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | 6.37% | -0.39% | -2.45% | 1.13% |
| Galectin Therapeutics Inc. (GALT)vs › | $241.69M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $245.79M | -1.78% | -948.17% | -2570.36% | -2570.36% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $239.25M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $246.29M | -3813.88% | -3607.01% | -5701.50% | -5701.50% |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $246.48M | -38.32% | -70.22% | -602.02% | -454.95% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | -1441.45% | -4661.83% | -5918.79% | -3944.51% |
| High Tide Inc. (HITI)vs › | $237.69M | 1.66% | 3.74% | -1.53% | 0.81% |
| Invivyd, Inc. (IVVD)vs › | $236.86M | -100.05% | -392.29% | -392.29% | -392.29% |
Gross Margin
99.8%
EBITDA Margin
32.2%
Operating Margin
31.4%
Net Margin
62.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 85.54% |
| 2023-12-31 | 175.18% |
| 2023-09-30 | -412.80% |
| 2023-06-30 | -223.12% |
| 2023-03-31 | -245.88% |
| 2022-12-31 | -205.90% |
| 2022-09-30 | -4018.33% |
| 2022-06-30 | -3431.55% |
| 2022-03-31 | -4622.57% |
| 2021-12-31 | -3894.01% |
| 2021-09-30 | -1685.27% |
| 2021-06-30 | -1287.65% |
| 2021-03-31 | 4.26% |
| 2020-12-31 | -2805.41% |
| 2020-09-30 | -4592.06% |
| 2020-06-30 | -5902.65% |
| 2020-03-31 | -5844.22% |
| 2019-12-31 | -4234.46% |
| 2019-09-30 | -6709.30% |
| 2019-06-30 | -6717.09% |
| 2019-03-31 | -8835.93% |
| 2018-12-31 | -2022.94% |
| 2018-09-30 | -1675.10% |
| 2018-06-30 | -1473.70% |
| 2018-03-31 | -1309.45% |
